On the chart of Recursion Pharmaceuticals (RXRX), there are clear signs of a potential trend reversal. The price has reached a key support level around $4.95, which has previously acted as a strong rebound zone. Currently, the stock appears to be stabilizing and forming a base for a possible upward move.
The moving averages (EMA) are starting to flatten, suggesting that selling pressure may be easing, while the RSI oscillator is in the oversold zone, further supporting a potential rebound scenario. If the price holds above support and breaks through the short-term downtrend line, a strong upward move toward $9.50 is possible — this level represents the next major technical resistance and a realistic target for a bullish impulse.
In summary, as long as the $4.95 support holds, the bullish scenario targeting $9.50 remains likely, especially if confirmed by increased volume and a breakout above the $5.50–$5.70 range.
Potential TP: 9.20 USD
⚠️ Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial or investment advice. Always conduct your own research or consult a licensed financial advisor before making investment decisions.
The moving averages (EMA) are starting to flatten, suggesting that selling pressure may be easing, while the RSI oscillator is in the oversold zone, further supporting a potential rebound scenario. If the price holds above support and breaks through the short-term downtrend line, a strong upward move toward $9.50 is possible — this level represents the next major technical resistance and a realistic target for a bullish impulse.
In summary, as long as the $4.95 support holds, the bullish scenario targeting $9.50 remains likely, especially if confirmed by increased volume and a breakout above the $5.50–$5.70 range.
Potential TP: 9.20 USD
⚠️ Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial or investment advice. Always conduct your own research or consult a licensed financial advisor before making investment decisions.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.